| Word Search (Top 10 - by date) |
Novartis Receives FDA Approval of Tekamlo(TM), a Single-pill Combination of Aliskiren and Amlodipine to Treat High Blood Pressure
Novartis
(August 27, 2010)
|
Novartis Receives Approval in China for Rasilez, a First-in-class Direct Renin Inhibitor for High Blood Pressure, the Leading Preventable Cause of Death in China
Novartis
(July 20, 2010)
|
Novartis Delivers Strong Financial Performance in Second Quarter, Underpinned by Increased Momentum in Innovation
Novartis
(July 15, 2010)
|
Teva Admits to Making False Statements in US Gianvi(™)
Bayer
(June 17, 2010)
|
Novartis Gains New Indication for Diovan®* for the Treatment of Children and Adolescents With High Blood Pressure in the EU
Novartis
(April 23, 2010)
|
Novartis Healthcare Portfolio Generates Strong Growth in First Quarter of 2010, Progress on Delivering Innovation, Growth and Productivity
Novartis
(April 20, 2010)
|
Synthon Announces Tentative Approval of Generic Amlodipine-valsartan Tablets
Synthon Pharmaceuticals
(April 02, 2010)
|
Crucell's Supervisory Board Nominates Mr. W. Burns, Mr. J. Shannon and Mr. G. Siber as New Board Members
Crucell
(March 15, 2010)
|
Novartis Achieves Record Results in 2009 as Momentum from Recently Launched Products Drives Growth Across Its Entire Healthcare Portfolio
Novartis
(January 26, 2010)
|
Three New Novartis Medicines Approved in Japan for Patients With Type 2 Diabetes, High Blood Pressure and Advanced Kidney Cancer
Novartis
(January 20, 2010)
|
|
|
|
|
EvaluatePharma® - the premier source for pharma and biotech analysis.
Expert integration of financial and product data across historic and forecast timeframes (1986 to 2016) delivers a vast array of analytics by product, company, therapy area, EphMRA ATC code, technology, patent status (expiry date/ number), deals (upfront/ milestones), license revenues (royalties/ co-promotion) and much more.
|
| Summary Product Name Information |
|
|
| Product Sales Summary 2007/08 |
|
Annual Sales WW - Sales
|
Growth per Year (%)
|
|
Rank1 |
Generic Name
|
Therapeutic Subcategory
|
2007 |
2008
|
2008 |
| Diovan2 |
|
|
|
5,012 |
5,740 |
|
+15% |
|
|
Note: Shaded Cells3 |
|
|
More Product Information for EvaluatePharma® subscribersSubscribers see:
- Sales (historic and forecast to 2016 where available) listed by the reporting company or companies, including royalty, license and JV revenue where applicable
- Details of all events impacting the product
- Detailed product information, including sales forecasts listed by the reporting company or companies, indications (approved and in trial)
|
Register to access more FREE content:
- 2009 Product Sales analysis
- Download analysis into Excel
- Search 2 yrs of company press releases
|